East Coast, USA-based biotech BioXcel Therapeutics (Nasdaq: BTAI) says it has finalized formulation development for its candidate BXCL501, with the aim of supporting a Phase III trial later in the year.
BioXcel is focused on using artificial intelligence to identify novel therapeutic approaches in neuroscience and immuno-oncology.
The firm says it has transitioned to automated manufacturing for its sublingual thin film, containing dexmedetomidine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze